Noteworthy, we observed a significant reduction of the phosphorylation of GSK3α/β, mTOR, p70S6K, RPS6 and TSC2 proteins in all DLBCL cells after treatment with tafasitamab plus mVNR. This evidence concerns the gene GSK3A and diffuse large B-cell lymphoma.